Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to “Hold” at Citigroup

Citigroup upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) to a hold rating in a research report released on Wednesday morning,Zacks.com reports.

Several other brokerages also recently commented on REGN. Evercore ISI lowered their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Morgan Stanley lowered their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. TD Cowen boosted their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Finally, Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Trading Down 3.4 %

Shares of Regeneron Pharmaceuticals stock traded down $26.59 on Wednesday, hitting $755.92. The stock had a trading volume of 394,565 shares, compared to its average volume of 526,043. The stock’s 50-day simple moving average is $992.70 and its two-hundred day simple moving average is $1,033.92. Regeneron Pharmaceuticals has a one year low of $753.69 and a one year high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $83.07 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 3.04 and a beta of 0.15.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.48% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Quent Capital LLC lifted its stake in Regeneron Pharmaceuticals by 5.1% during the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 19 shares during the period. Dorsey & Whitney Trust CO LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 26.8% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 587 shares of the biopharmaceutical company’s stock valued at $565,000 after buying an additional 124 shares during the period. Acadian Asset Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 37.2% in the 1st quarter. Acadian Asset Management LLC now owns 62,141 shares of the biopharmaceutical company’s stock worth $59,794,000 after buying an additional 16,856 shares during the last quarter. Cercano Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $36,953,000. Finally, Edgestream Partners L.P. bought a new position in Regeneron Pharmaceuticals in the first quarter valued at about $7,352,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.